Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (2855)	5/19/1999 4:12:00 PM
From: Biomaven	Respond to of 10280

RCM - Cisapride and norcisapride are likely to have different indications - the metabolite really sounds like it is a different drug than the parent. With Seldane/Allegra there was no difference in what they did, just in side effects, and so there was no justification for keeping Seldane on the market. I'm not counting any norcisapride chickens until J&J at least advances it to Phase III from Phase II. When a metabolite sounds this different it becomes a little more like a new drug, which means there is always the possibility of an unpleasant surprise. Peter